Author:
Wachter H.,von Loeffelholz C.,Thomas-Rüddel D. O.,Bargenda S.,Birkenfeld A. L.,Bauer M.,Ehler J.
Funder
Universitätsklinikum Jena
Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. S3-Leitlinie Nationale Versorgungsleitlinie (NVL) Typ-2-Diabetes, AWMF-Register-Nr. nvl-001.
2. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators. (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128. https://doi.org/10.1056/NEJMoa1504720
3. Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, Komajda M, Miller A, Pehrson S, Teerlink JR, Brueckmann M, Jamal W, Zeller C, Schnaidt S, Zannad F (2021) Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial. Circulation 143(4):326–336. https://doi.org/10.1161/CIRCULATIONAHA.120.051783 (Erratum in: Circulation. 2021 Jan 26;143(4):e30. PMID: 33081531)
4. Theresa A McDonagh, Marco Metra, Marianna Adamo, Roy S Gardner, Andreas Baumbach, Michael Böhm, Haran Burri, Javed Butler, Jelena Čelutkienė, Ovidiu Chioncel, John G F Cleland, Maria Generosa Crespo-Leiro, Dimitrios Farmakis, Martine Gilard, Stephane Heymans, Arno W Hoes, Tiny Jaarsma, Ewa A Jankowska, Mitja Lainscak, Carolyn S P Lam, Alexander R Lyon, John J V McMurray, Alexandre Mebazaa, Richard Mindham, Claudio Muneretto, Massimo Francesco Piepoli, Susanna Price, Giuseppe M C Rosano, Frank Ruschitzka, Anne Kathrine Skibelund, ESC Scientific Document Group , 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal, Volume 44, Issue 37, 1 October 2023, Pages 3627–3639, https://doi.org/10.1093/eurheartj/ehad195
5. Mosley JF 2nd, Smith L, Everton E, Fellner C (2015) Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type‑2 diabetes: a drug class overview. P T 40(7):451–462